Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

8(57.1%)

Phase 1

3(21.4%)

Phase 3

3(21.4%)

14Total

Phase 2(8)

Phase 1(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT04380532Phase 1Unknown

Tableted COVID-19 Therapeutic Vaccine

Role: lead

NCT04377243Phase 2Unknown

Immunotherapy of Chronic Kidney Failure

Role: lead

NCT03042182Phase 1Unknown

Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Role: lead

NCT03572361Phase 2Unknown

Open Label Immunotherapy Trial for Breast Cancer

Role: lead

NCT03165591Phase 1Unknown

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer

Role: lead

NCT02256514Phase 2Unknown

Open Label Trial of Immunotherapy for Advanced Liver Cancer

Role: lead

NCT03550755Phase 2Unknown

Immunotherapy of Cervical Cancer With V3-Cervix

Role: lead

NCT03556566Phase 2Unknown

Open Label Immunotherapy Trial for Ovarian Cancer

Role: lead

NCT01977768Phase 3Completed

TB Immunotherapy Trial With Heat-killed M. Vaccae

Role: lead

NCT03916757Phase 2Unknown

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer

Role: lead

NCT03340324Phase 2Unknown

Open Label Immunotherapy of Endometriosis

Role: lead

NCT03042741Phase 3Unknown

Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity

Role: lead

NCT02232490Phase 3Unknown

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

Role: lead

NCT03550703Phase 2Unknown

Open Label Immunotherapy of Myoma

Role: lead

All 14 trials loaded